StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.43−0.07 (-13.14%)

Close on Nov 17, 2026Market cap $14.51MP/E –Yield –

Pasithea Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Pasithea Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.73M, up 54.0% year over year. For fiscal 2025 it was $7.98M, up 10.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.98M+10.9%
FY2024Dec 31, 2024$7.20M-11.1%
FY2023Dec 31, 2023$8.10M+203.9%
FY2022Dec 31, 2022$2.67M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.69M+71.5%
Q1 FY2026Mar 31, 2026$2.94M+70.1%
Q4 FY2025Dec 31, 2025$2.74M+81.8%
Q3 FY2025Sep 30, 2025$1.36M-14.1%
Q2 FY2025Jun 30, 2025$2.15M-8.9%
Q1 FY2025Mar 31, 2025$1.73M-1.1%
Q4 FY2024Dec 31, 2024$1.51M-54.9%
Q3 FY2024Sep 30, 2024$1.58M-2.7%
Q2 FY2024Jun 30, 2024$2.36M+16.3%
Q1 FY2024Mar 31, 2024$1.75M+59.6%
Q4 FY2023Dec 31, 2023$3.35M+141.7%
Q3 FY2023Sep 30, 2023$1.62M+27.0%
Q2 FY2023Jun 30, 2023$2.03M–
Q1 FY2023Mar 31, 2023$1.10M–
Q4 FY2022Dec 31, 2022$1.39M–
Q3 FY2022Sep 30, 2022$1.28M–

More Pasithea Therapeutics figures

See a number that looks wrong?